drugset / Trial / NCT04228315
Biomarkers of P. Vivax Relapse
Unknown
100 enrolled
Armed Forces Research Institute of Medical Sciences, Thailand
University of North Carolina, Chapel Hill · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills the infection in the blood, it can continue to hide quietly in the liver, later re-emerging into the blood and causing another episode of malaria illness (relapse). This clinical trial aims to enroll patient with P. vivax infections and try to detect signals in blood, urine and/or saliva coming from the silent liver stages to help identify who could benefit from treatment with primaquine. It also will explore if certain factors of patients negatively impact primaquine efficacy.
Timeline
- Start
- 2019-11-19
- Primary completion
- 2021-06-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Primaquine | Small molecule | 15 mg | Oral |